Abstract
Oxidative stress, linked to Abeta-lipid interactions, plays a pathogenetic role in Alzheimers disease. We investigated modifications of lipid peroxidation products in plasma of 52 AD patients, 42 healthy controls and 16 patients with amyotrophic lateral sclerosis, a neurodegenerative disease where oxidative stress also plays a pathogenetic role. Final lipid peroxidation products were measured in plasma by thiobarbituric acid reactive substances (TBARS) assay before and after ex vivo oxidative stress catalysed by copper. There were no significant changes at basal conditions, but after copperinduced oxidation TBARS levels were higher in AD patients (19.0 μM ± 2.2) versus both controls (5.2 μM ± 0.8, p < 0.001) and ALS patients (7.6 M ± 2.1, p < 0.01). Stimulated TBARS levels were significantly higher in mild and moderate AD (p < 0.0001) with respect to controls, but not in severe AD patients, with a significant inverse correlation between disease severity and lipid peroxidation (p < 0.005, r2=0.21). Treatment of a subgroup (13) of mild and moderate AD patients with vitamin C and E for three months decreased plasma lipoperoxidation susceptibility by 60%. Thus, oxidative stress, expressed as ex vivo susceptibility to lipid peroxidation, appears to be an early phenomenon, probably related to AD pathogenetic mechanisms.
Keywords: alzheimers disease, oxidative stress, tbars, beta amyloid, copper
Current Alzheimer Research
Title: Increased Susceptibility to Plasma Lipid Peroxidation in Alzheimer Disease Patients
Volume: 1 Issue: 2
Author(s): Carmen Galbusera, Maurizio Facheris, Fulvio Magni, Gloria Galimberti, Gessica Sala, Lucia Tremolada, Valeria Isella, Franca Rosa Guerini, Ildebrando Appollonio, Marzia Galli-Kienle and Carlo Ferrarese
Affiliation:
Keywords: alzheimers disease, oxidative stress, tbars, beta amyloid, copper
Abstract: Oxidative stress, linked to Abeta-lipid interactions, plays a pathogenetic role in Alzheimers disease. We investigated modifications of lipid peroxidation products in plasma of 52 AD patients, 42 healthy controls and 16 patients with amyotrophic lateral sclerosis, a neurodegenerative disease where oxidative stress also plays a pathogenetic role. Final lipid peroxidation products were measured in plasma by thiobarbituric acid reactive substances (TBARS) assay before and after ex vivo oxidative stress catalysed by copper. There were no significant changes at basal conditions, but after copperinduced oxidation TBARS levels were higher in AD patients (19.0 μM ± 2.2) versus both controls (5.2 μM ± 0.8, p < 0.001) and ALS patients (7.6 M ± 2.1, p < 0.01). Stimulated TBARS levels were significantly higher in mild and moderate AD (p < 0.0001) with respect to controls, but not in severe AD patients, with a significant inverse correlation between disease severity and lipid peroxidation (p < 0.005, r2=0.21). Treatment of a subgroup (13) of mild and moderate AD patients with vitamin C and E for three months decreased plasma lipoperoxidation susceptibility by 60%. Thus, oxidative stress, expressed as ex vivo susceptibility to lipid peroxidation, appears to be an early phenomenon, probably related to AD pathogenetic mechanisms.
Export Options
About this article
Cite this article as:
Galbusera Carmen, Facheris Maurizio, Magni Fulvio, Galimberti Gloria, Sala Gessica, Tremolada Lucia, Isella Valeria, Guerini Rosa Franca, Appollonio Ildebrando, Galli-Kienle Marzia and Ferrarese Carlo, Increased Susceptibility to Plasma Lipid Peroxidation in Alzheimer Disease Patients, Current Alzheimer Research 2004; 1 (2) . https://dx.doi.org/10.2174/1567205043332171
DOI https://dx.doi.org/10.2174/1567205043332171 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Current Diabetes Proteomics: From the Perspectives of Label- free Quantification and Biomarker Selection
Current Drug Targets Partnerships Between Philanthropy, Government and Investors are Needed to Advance Drug Discovery for Neurodegenerative Diseases
Current Alzheimer Research Lewy Bodies: A Spectator or Salient Killer?
CNS & Neurological Disorders - Drug Targets Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Involvement of Advanced Glycation End-products (AGEs) in Alzheimers Disease
Current Alzheimer Research Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Microtubule-Directed Therapeutic Strategy for Neurodegenerative Disorders: Starting From the Basis and Looking on the Emergences
Current Pharmaceutical Design Relevance of the Chronobiological and Non-chronobiological Actions of Melatonin for Enhancing Therapeutic Efficacy in Neurodegenerative Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Alzheimer Research Human Embryonic Stem Cell Therapies for Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design Muscle Atrophy Classification: The Need for a Pathway-Driven Approach
Current Pharmaceutical Design Spinal Cord Injury Changes Cytokine Transport
CNS & Neurological Disorders - Drug Targets Parkinson's Disease: A Role for the Immune System
Current Molecular Pharmacology TrkB Receptor Agonist 7, 8 Dihydroxyflavone Triggers Profound Gender- Dependent Neuroprotection in Mice After Perinatal Hypoxia and Ischemia
CNS & Neurological Disorders - Drug Targets Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets